FDA Approves String of Infectious Disease Vaccines Amid Ongoing Pandemic Efforts

The US FDA has issued approvals and expanded indications for various infectious disease vaccines this year. As of August 31, 2026, GSK's Arexvy has gained clearance for younger at-risk adults, while Moderna secured approval for its first mRNA flu vaccine. Merck's Capvaxive has also expanded into pediatric populations with underlying conditions.

The approvals cover RSV, influenza, pneumococcal disease, and COVID-19 vaccines. GSK's Arexvy is a notable addition, as it provides protection against the respiratory syncytial virus (RSV) for younger adults at risk of severe illness. Moderna's mRNA flu vaccine marks an important milestone in the development of next-generation flu vaccines.

The FDA has been actively working on approving and expanding indications for various vaccines this year, highlighting the importance of continued research and development in the field of infectious disease prevention.